ADVERTISEMENT
Leading Oncologists Examine Evolving Strategies in HER2-Low Diagnosis and Treatment in Metastatic Breast Cancer
In this expert roundtable, five leading breast cancer specialists discuss the changing dynamics of HER2-low and HER2-positive breast cancer. They delve into the pathophysiology, dissect current clinical guidelines, and analyze the significant role HER2 testing plays in treatment choices. The experts examine HER2-targeted antibody-drug conjugates (ADCs), delve into the nuances of diagnosing HER2-low cancer, evaluate key clinical trial outcomes, and assess the impact of National Comprehensive Cancer Network (NCCN) guidelines on treating HER2 breast cancer. Be sure to watch our three-part video series for the most recent updates!
This roundtable is sponsored by Daiichi Sankyo.
HER2-Low Breast Cancer Roundtable: Decoding HER2-Low Expression in Metastatic Breast Cancer
This video discusses HER2 expression in metastatic breast cancer, including the nuances of HER2-low diagnosis, clinicopathologic differences between HER2-low and HER2-positive expression, and the implications for managing the disease.
HER2-Low Breast Cancer Roundtable: Navigating Latest Guidelines & HER2-Targeted Treatments in Metastatic Breast Cancer
This video highlights the latest clinical practice guidelines for HER2-low breast cancer, explores the role of HER2-targeted ADCs, reviews pivotal clinical trial data, and discusses the implications of NCCN guidelines on the HER2 treatment landscape.
HER2-Low Breast Cancer Roundtable: Deep Dive Into HER2 Testing in Metastatic Breast Cancer Treatment
This video discusses the timing and impact of repeat HER2 testing on treatment choices and patient outcomes, challenges with HER2 test interpretation, and potential benefits from HER2-targeted therapies.
Access additional insights and resources on HER2 in breast cancer below:
